Story perspectives

Republicans Demand Review of Mifepristone Generic Approval

10/10/2025

Summary

Republicans Demand Reassessment

Fifty-one Republican senators urged Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Martin Makary to reevaluate the approval of a new generic version of mifepristone.
They cited a study showing a higher complication rate than previously reported.
They called for reinstating safeguards removed by the Biden administration, including in-person dispensing.
The FDA approved the generic version, saying it is equivalent to the brand-name drug.

Summary

Louisiana Sues FDA

Louisiana filed a lawsuit against the U.S. Food and Drug Administration challenging approval of mail-order abortion pills including mifepristone.
Attorney General Liz Murrill says the practice violates Louisiana law, as the state bans abortion at all gestational stages.
The suit argues that removing in-person dispensing requirements increased illegal shipments of abortion drugs.
Pro-life advocates, Family Research Council President Tony Perkins, back the suit and push for safety protocols for mifepristone.

History

Historical Context

The 1973 Supreme Court decision Roe v. Wade legalized abortion nationwide, establishing a constitutional right to privacy under the Fourteenth Amendment. This ruling ignited ongoing debates about reproductive rights, leading to significant legislative actions, including the 2000 FDA approval of mifepristone for medical abortions. Recent challenges, such as Louisiana's lawsuit, reflect the persistent tensions surrounding abortion access and regulation in the U.S.

1 of 3

Republicans Demand Reassessment

Fifty-one Republican senators urged Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Martin Makary to reevaluate the approval of a new generic version of mifepristone.
They cited a study showing a higher complication rate than previously reported.
They called for reinstating safeguards removed by the Biden administration, including in-person dispensing.
The FDA approved the generic version, saying it is equivalent to the brand-name drug.

1 / 3